Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OAC2 是一种 Oct4 激活剂,通过 Oct4 基因启动子激活表达, 通过提高胚胎成纤维细胞诱导多能干细胞的产生速率来提高重编程效率,是 OAC1 的类似物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 297 | 现货 | ||
10 mg | ¥ 493 | 现货 | ||
25 mg | ¥ 987 | 现货 | ||
50 mg | ¥ 1,750 | 现货 | ||
100 mg | ¥ 3,190 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 448 | 现货 |
产品描述 | OAC2 is an Oct4 activator which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1. |
体外活性 | Octamer-binding transcription factor 4 (Oct4) is a master regulator of the induction and maintenance of cellular pluripotency, and has crucial roles in early stages of differentiation. It is the only factor that cannot be substituted by other members of the same protein family to induce pluripotency[1]. Oct4 has been shown to be an essential regulator of embryonic stem cell (ESC) pluripotency and key to the reprogramming process. OAC2 is a structural analog of OAC1 that activates both Oct4 and Nanog reporters to a similar extent as OAC1. OAC1 and its two structural analogs OAC2 and OAC3 enhances reprogramming efficiency fourfold, up to as high as 2.75%, and accelerates the appearance of iPSC colonies 3 to 4 d when used in combination with the four reprogramming factors, Oct4, Sox2, Klf4, and c-Myc[2]. |
细胞实验 | The Oct4-luc or Nanog-luc cells are treated with compound OAC1 or its structural analogs OAC2, OAC3 at 1 μM concentration or at indicated concentrations. Other compounds used include 2 μM BIO, 2 μM BIX, 2 μM 5'-azacytidine, 25 μg/mL Vitamin C, 10 nM Am580, 5 μM tranylcypromine, and 0.5 mM valporic acid. Luciferase reporter assays are performed 24 h after compound treatment or at indicated time points. For Topflash reporter assays, 0.2 μg β-catenin–responsive Topflash reporter gene plasmid is introduced into CV1 cells using trasfection. Compounds are added 6 h after transfection. Luciferase activity is measured 48 h after compound treatment using the Glo Luciferase Assay System[2]. |
分子量 | 236.27 |
分子式 | C15H12N2O |
CAS No. | 6019-39-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23.6 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.2324 mL | 21.1622 mL | 42.3245 mL | 105.8111 mL |
5 mM | 0.8465 mL | 4.2324 mL | 8.4649 mL | 21.1622 mL | |
10 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL | 10.5811 mL | |
20 mM | 0.2116 mL | 1.0581 mL | 2.1162 mL | 5.2906 mL | |
50 mM | 0.0846 mL | 0.4232 mL | 0.8465 mL | 2.1162 mL | |
100 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0581 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OAC2 6019-39-2 Membrane transporter/Ion channel OCT Slc22a3 Oct3/4 inhibit POU5F1 OAC 2 OAC-2 Inhibitor inhibitor